Evoke Pharma Company Profile (NASDAQ:EVOK)

About Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma logoEvoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EVOK
  • CUSIP: N/A
  • Web: www.evokepharma.com
Capitalization:
  • Market Cap: $32.12 million
  • Outstanding Shares: 15,388,000
Average Prices:
  • 50 Day Moving Avg: $2.72
  • 200 Day Moving Avg: $2.51
  • 52 Week Range: $1.35 - $11.11
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.08
  • P/E Growth: -0.08
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.31 per share
  • Price / Book: 8.42
Profitability:
  • Return on Equity: -612.23%
  • Return on Assets: -142.10%
Debt:
  • Current Ratio: 10.70%
  • Quick Ratio: 10.70%
Misc:
  • Average Volume: 254,852 shs.
  • Beta: 1.06
  • Short Ratio: 0.76
 

Frequently Asked Questions for Evoke Pharma (NASDAQ:EVOK)

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How were Evoke Pharma's earnings last quarter?

Evoke Pharma Inc (NASDAQ:EVOK) announced its earnings results on Monday, May, 15th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. During the same period in the previous year, the firm earned ($0.45) EPS. View Evoke Pharma's Earnings History.

Where is Evoke Pharma's stock going? Where will Evoke Pharma's stock price be in 2017?

9 analysts have issued 12-month price objectives for Evoke Pharma's shares. Their predictions range from $6.00 to $9.00. On average, they expect Evoke Pharma's stock price to reach $8.20 in the next year. View Analyst Ratings for Evoke Pharma.

What are analysts saying about Evoke Pharma stock?

Here are some recent quotes from research analysts about Evoke Pharma stock:

  • 1. FBR & Co analysts commented, "We think agreements reached with the FDA have provided Evoke Pharma with a clear regulatory path for advancing Gimoti as a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. The company has maintained its projection for filing a New Drug Application (NDA) for Gimoti’s FDA approval in late 2017 or early 2018. One particularly key positive development in 1Q17 was gaining an agreement that a Human Factors Validation Study would not be required prior to filing the NDA. We think investors have not fully recognized the value of this agreement, as conducting this study would have significantly delayed Gimoti’s approval. We look for near-term investor recognition of this and other de-risking factors to increase and result in positive stock outperformance vs. the NASDAQ Biotechnology Index in 2017 (up 30% versus up 11% YTD, respectively)." (5/18/2017)
  • 2. According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. " (3/20/2017)
  • 3. Ascendiant Capital Markets analysts commented, "Maintaining our BUY rating, but raising our 12-month price target to $6 from $5, which is based on an NPV analysis. Though we acknowledge that it is still at an early stage, we believe the large market potential presents a high reward for the risks." (3/16/2017)
  • 4. Rodman & Renshaw analysts commented, "We are expecting Evoke to report top-line data within the next couple of weeks from the Phase 3 trial of its lead candidate, EVK-001 (intranasal metoclopramide), in women with diabetic gastroparesis. We anticipate that these results, if positive, should enable Evoke to file directly for approval of EVK-001 in the U.S. via the 505(b)(2) pathway. In anticipation of positive results from this trial, we reiterate our Buy rating and 12-month price target of $27.00 on EVOK shares. Phase 3 trial robustly powered, in our view. The METO-IN-003 trial has enrolled roughly 200 adult women with diabetic gastroparesis, and was formally completed at the beginning of June. The primary endpoint is change from baseline in symptom score at week 4 utilizing a proprietary Patient Reported Outcome (PRO) instrument. The study size reflects 90% power (alpha=0.05 two-sided, SD=0.65) to detect a mean difference of 0.3 between the treatment and placebo groups. We note that the Phase 2b EVK-001 trial reached statistical significance in women (p=0.0247) and that the drug group showed a >50% improvement in mean gastroparesis total symptom score change from baseline." (7/11/2016)

Who are some of Evoke Pharma's key competitors?

Who owns Evoke Pharma stock?

Evoke Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sphera Funds Management LTD. (4.06%), Vanguard Group Inc. (3.70%), State Treasurer State of Michigan (2.37%) and California Public Employees Retirement System (0.30%). Company insiders that own Evoke Pharma stock include Kenneth J Widder and Parters Vii L P Domain. View Institutional Ownership Trends for Evoke Pharma.

Who bought Evoke Pharma stock? Who is buying Evoke Pharma stock?

Evoke Pharma's stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Vanguard Group Inc. and State Treasurer State of Michigan. View Insider Buying and Selling for Evoke Pharma.

How do I buy Evoke Pharma stock?

Shares of Evoke Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Evoke Pharma stock cost?

One share of Evoke Pharma stock can currently be purchased for approximately $2.61.

Analyst Ratings

Consensus Ratings for Evoke Pharma (NASDAQ:EVOK) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $8.20 (214.18% upside)

Analysts' Ratings History for Evoke Pharma (NASDAQ:EVOK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017FBR & CoReiterated RatingBuy$9.00LowView Rating Details
3/16/2017HC WainwrightSet Price TargetBuy$9.00MediumView Rating Details
3/16/2017Ascendiant Capital MarketsBoost Price TargetIn-Line$5.00 -> $6.00HighView Rating Details
3/16/2017Rodman & RenshawReiterated RatingBuy -> Buy$6.00 -> $9.00HighView Rating Details
1/30/2017LaidlawUpgradeNeutral -> Buy$8.00N/AView Rating Details
8/16/2016Noble FinancialReiterated RatingHoldN/AView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
7/18/2016Feltl & Co.DowngradeStrong-Buy -> SellN/AView Rating Details
7/18/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Evoke Pharma (NASDAQ:EVOK)
Earnings by Quarter for Evoke Pharma (NASDAQ:EVOK)
Earnings History by Quarter for Evoke Pharma (NASDAQ:EVOK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.16)($0.14)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.19)($0.12)ViewN/AView Earnings Details
11/9/2016Q316($0.27)($0.29)ViewListenView Earnings Details
8/15/2016Q216($0.43)($0.41)ViewListenView Earnings Details
5/11/2016Q116($0.41)($0.45)ViewListenView Earnings Details
3/10/2016Q415($0.45)($0.37)ViewListenView Earnings Details
11/12/2015Q315($0.56)($0.42)ViewListenView Earnings Details
8/13/2015Q215($0.60)($0.52)ViewListenView Earnings Details
5/14/2015Q115($0.55)($0.58)ViewListenView Earnings Details
3/4/2015Q414($0.80)($0.48)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.78)($0.63)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.73)($0.59)ViewN/AView Earnings Details
5/13/2014Q114($0.38)($0.49)ViewN/AView Earnings Details
3/25/2014Q413($0.16)($0.27)ViewN/AView Earnings Details
11/13/2013Q3 13($0.10)($0.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Evoke Pharma (NASDAQ:EVOK)
2017 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.17)($0.17)($0.17)
Q2 20171($0.13)($0.13)($0.13)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Evoke Pharma (NASDAQ:EVOK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Evoke Pharma (NASDAQ:EVOK)
Insider Ownership Percentage: 30.50%
Institutional Ownership Percentage: 5.60%
Insider Trades by Quarter for Evoke Pharma (NASDAQ:EVOK)
Institutional Ownership by Quarter for Evoke Pharma (NASDAQ:EVOK)
Insider Trades by Quarter for Evoke Pharma (NASDAQ:EVOK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2017Kenneth J WidderDirectorBuy450,000$2.90$1,305,000.00View SEC Filing  
5/26/2016Parters Vii L P DomainMajor ShareholderSell344,120$4.70$1,617,364.00View SEC Filing  
4/27/2016Parters Vii L P DomainMajor ShareholderSell5,095$5.07$25,831.65View SEC Filing  
4/25/2016Parters Vii L P DomainMajor ShareholderSell1,492$5.20$7,758.40View SEC Filing  
4/20/2016Parters Vii L P DomainMajor ShareholderSell41,478$5.35$221,907.30View SEC Filing  
4/11/2016Parters Vii L P DomainMajor ShareholderSell4,348$5.22$22,696.56View SEC Filing  
4/8/2016Parters Vii L P DomainMajor ShareholderSell51,004$5.28$269,301.12View SEC Filing  
8/18/2015Parters Vii L P DomainMajor ShareholderSell11,836$7.02$83,088.72View SEC Filing  
4/16/2015Parters Vii L P DomainMajor ShareholderSell50,163$7.29$365,688.27View SEC Filing  
9/23/2014Todd C BradyDirectorBuy4,000$5.70$22,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Evoke Pharma (NASDAQ:EVOK)
Latest Headlines for Evoke Pharma (NASDAQ:EVOK)
Source:
DateHeadline
americanbankingnews.com logoQ2 2017 Earnings Estimate for Evoke Pharma Inc Issued By FBR & Co (EVOK)
www.americanbankingnews.com - May 19 at 7:24 AM
americanbankingnews.com logoFBR & Co Reiterates "Buy" Rating for Evoke Pharma Inc (EVOK)
www.americanbankingnews.com - May 18 at 4:40 PM
globenewswire.com logoEvoke Pharma Reports First Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - May 17 at 10:50 AM
reuters.com logoBRIEF-Evoke Pharma Q1 loss per share $0.37 - Reuters
www.reuters.com - May 16 at 10:04 PM
nasdaq.com logoEvoke Pharma Reports First Quarter 2017 Results - Nasdaq
www.nasdaq.com - May 16 at 10:04 PM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Issues Quarterly Earnings Results, Misses Estimates By $0.21 EPS
www.americanbankingnews.com - May 15 at 9:20 PM
finance.yahoo.com logoInvestor Network: Evoke Pharma, Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 4:46 PM
finance.yahoo.com logoEvoke Pharma Reports First Quarter 2017 Results
finance.yahoo.com - May 15 at 4:46 PM
americanbankingnews.com logo-$0.14 Earnings Per Share Expected for Evoke Pharma Inc (EVOK) This Quarter
www.americanbankingnews.com - May 15 at 2:22 PM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 12 at 10:58 PM
globenewswire.com logoEvoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week ... - GlobeNewswire (press release)
globenewswire.com - May 11 at 5:44 PM
streetinsider.com logoEvoke Pharma (EVOK) Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at DDW
www.streetinsider.com - May 11 at 3:13 AM
reuters.com logoBRIEF-Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial
www.reuters.com - May 11 at 3:13 AM
nasdaq.com logoEvoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week ... - Nasdaq
www.nasdaq.com - May 10 at 5:12 PM
streetinsider.com logoForm 4 Evoke Pharma Inc For: May 03 Filed by: GARNER CAM L - StreetInsider.com
www.streetinsider.com - May 7 at 5:19 PM
americanbankingnews.com logoEvoke Pharma (EVOK) Receiving Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 2 at 3:38 PM
finance.yahoo.com logoEvoke Pharma Schedules Conference Call and Webcast for First Quarter 2017 Financial Results
finance.yahoo.com - May 1 at 4:54 PM
americanbankingnews.com logoEvoke Pharma (EVOK) Receiving Somewhat Critical News Coverage, Study Shows
www.americanbankingnews.com - April 25 at 1:09 PM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Expected to Post Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 24 at 9:20 PM
streetinsider.com logoEvoke Pharma (EVOK) Confirms Collaboration with Spaulding Clinical Research for the Gimoti Comparative Exposure Pharmacokinetic Trial
www.streetinsider.com - April 19 at 12:12 PM
americanbankingnews.com logoEvoke Pharma (EVOK) Receives Media Sentiment Score of 0.50
www.americanbankingnews.com - April 19 at 11:36 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Goldman, Cardinal Health, Johnson & Johnson
www.nasdaq.com - April 18 at 11:45 AM
reuters.com logoBRIEF-Evoke Pharma announces collaboration with Spaulding Clinical Research
www.reuters.com - April 18 at 11:45 AM
finance.yahoo.com logoEvoke Pharma Announces Collaboration with Spaulding Clinical Research for the Gimoti Comparative Exposure Pharmacokinetic Trial
finance.yahoo.com - April 18 at 11:45 AM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 17 at 10:57 PM
finance.yahoo.com logoPositive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma’s Proposed Comparative Exposure PK Trial for Gimoti NDA
finance.yahoo.com - April 7 at 9:42 AM
bloomberg.com logoCompany Overview of Evoke Pharma, Inc.
www.bloomberg.com - March 29 at 11:29 AM
globenewswire.com logoEvoke Pharma's Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017 - GlobeNewswire (press release)
globenewswire.com - March 23 at 10:37 PM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 23 at 1:05 PM
finance.yahoo.com logoEVOKE PHARMA INC Financials
finance.yahoo.com - March 22 at 5:17 PM
streetinsider.com logoEvoke Pharma (EVOK) Announces Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at DDW
www.streetinsider.com - March 21 at 10:21 PM
finance.yahoo.com logoEvoke Pharma’s Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017
finance.yahoo.com - March 21 at 8:32 AM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:34 PM
americanbankingnews.com logoAnalysts Set Expectations for Evoke Pharma Inc's FY2018 Earnings (EVOK)
www.americanbankingnews.com - March 20 at 11:53 AM
americanbankingnews.com logoEvoke Pharma Inc (EVOK) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - March 16 at 2:30 AM
us.rd.yahoo.com logoEvoke Pharma Reports Fourth Quarter and Full Year 2016 Results
us.rd.yahoo.com - March 15 at 5:28 PM
us.rd.yahoo.com logo4:09 pm Evoke Pharma reports Q4; plans to be ready to finalize and submit NDA for Gimoti by late 2017 or early 2018
us.rd.yahoo.com - March 15 at 5:28 PM
biz.yahoo.com logoEVOKE PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 15 at 5:28 PM
biz.yahoo.com logoQ4 2016 Evoke Pharma Inc Earnings Release - After Market Close
biz.yahoo.com - March 15 at 7:31 AM
globenewswire.com logoEvoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Full-Year 2016 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 8 at 10:55 PM
finance.yahoo.com logoEvoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Full-Year 2016 Financial Results
finance.yahoo.com - March 7 at 11:41 AM
finance.yahoo.com logoEvoke Pharma Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
finance.yahoo.com - March 6 at 9:49 AM
streetinsider.com logoForm 4 Evoke Pharma Inc For: Feb 28 Filed by: D'Onofrio Matthew J - StreetInsider.com
www.streetinsider.com - March 3 at 3:24 AM
streetinsider.com logoForm 3 Evoke Pharma Inc For: Feb 22 Filed by: LATTERELL PATRICK F
www.streetinsider.com - February 24 at 10:59 PM
streetinsider.com logoEvoke Pharma (EVOK) Plans Offering of Common Stock - StreetInsider.com
www.streetinsider.com - February 17 at 9:18 AM
reuters.com logoBRIEF-Evoke Pharma announces proposed public offering of common stock
www.reuters.com - February 16 at 5:01 PM
rttnews.com logoEvoke Pharma Inc. (EVOK) Has Jumped To A 6-Month High On FDA Exemption
www.rttnews.com - February 16 at 5:01 PM
finance.yahoo.com logoFDA Exempts Evoke from Requirement for Human Factor Validation Study
finance.yahoo.com - February 16 at 5:01 PM
biz.yahoo.com logoEVOKE PHARMA INC Files SEC form 8-K, Other Events
biz.yahoo.com - February 16 at 5:01 PM
marketwatch.com logoEvoke Pharma's stock soars after FDA exempts Gimoti from HF Validation
www.marketwatch.com - February 16 at 5:01 PM

Social

Chart

Evoke Pharma (EVOK) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff